Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome.
Autorzy:
Holkova B; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA. Shafer D; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA. Yazbeck V; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA. Dave S; Department of Medicine, Duke University, Durham, NC, USA. Bose P; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA. TombesMB; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA. Shrader E; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA. Wan W; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.; Department of Statistics, Virginia Commonwealth University, Richmond, VA, USA. Bandyopadhyay D; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.; Department of Statistics, Virginia Commonwealth University, Richmond, VA, USA. Weir C; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA. Collins EB; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA. Garnett A; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA. Kmieciak M; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA. Roberts JD; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA. Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Grant S; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.; Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA, USA.; Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA.; The Institute for Molecular Medicine, Virginia Commonwealth University, Richmond, VA, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2021 May; Vol. 62 (5), pp. 1187-1194. Date of Electronic Publication: 2020 Dec 28.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.
Autorzy:
Holkova B; a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.; b Department of Internal Medicine , Virginia Commonwealth University , Richmond , VA , USA. Yazbeck V; a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.; b Department of Internal Medicine , Virginia Commonwealth University , Richmond , VA , USA. Kmieciak M; a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA. Bose P; a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA. Ma S; c Division of Hematology and Oncology , Robert H. Lurie Comprehensive Cancer Center, Northwestern University , Chicago , IL , USA. Kimball A; d Marlene and Stewart Greenebaum Cancer Center, University of Maryland , Baltimore , MD , USA. TombesMB; a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA. Shrader E; a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA. Wan W; e Department of Statistics , Virginia Commonwealth University , Richmond , VA , USA. Weir-Wiggins C; a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA. Singh A; a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA. Hogan KT; a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA. Conine S; a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA. Sankala H; a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA. Roberts JD; a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA. Shea TC; f Department of Hematology/Oncology , Lineberger Comprehensive Cancer Center, University of North Carolina , Chapel Hill , NC , USA. Grant S; a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.; b Department of Internal Medicine , Virginia Commonwealth University , Richmond , VA , USA.; g Department of Microbiology and Immunology , Virginia Commonwealth University , Richmond , VA , USA.; h Department of Biochemistry and Molecular Biology , Virginia Commonwealth University , Richmond , VA , USA.; i The Institute for Molecular Medicine, Virginia Commonwealth University , Richmond , VA , USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2017 Jun; Vol. 58 (6), pp. 1349-1357. Date of Electronic Publication: 2017 Jan 19.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.
Autorzy:
Holkova B; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .; b Department of Internal Medicine , Virginia Commonwealth University , Richmond , VA , USA . Kmieciak M; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA . Bose P; c University of Texas MD Anderson Cancer Center , Houston , TX , USA . Yazbeck VY; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .; b Department of Internal Medicine , Virginia Commonwealth University , Richmond , VA , USA . Barr PM; d James P. Wilmot Cancer Center, University of Rochester , Rochester , NY , USA . TombesMB; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA . Shrader E; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA . Weir-Wiggins C; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA . Rollins AD; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA . Cebula EM; d James P. Wilmot Cancer Center, University of Rochester , Rochester , NY , USA . Pierce E; d James P. Wilmot Cancer Center, University of Rochester , Rochester , NY , USA . Herr M; d James P. Wilmot Cancer Center, University of Rochester , Rochester , NY , USA . Sankala H; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA . Hogan KT; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA . Wan W; e Department of Biostatistics , Virginia Commonwealth University , Richmond , VA , USA . Feng C; d James P. Wilmot Cancer Center, University of Rochester , Rochester , NY , USA .; f Department of Biostatistics and Computational Biology , University of Rochester , Rochester , NY , USA . Peterson DR; f Department of Biostatistics and Computational Biology , University of Rochester , Rochester , NY , USA . Fisher RI; g Fox Chase Cancer Center , Temple Health , Philadelphia , PA , USA . Grant S; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .; b Department of Internal Medicine , Virginia Commonwealth University , Richmond , VA , USA .; h Department of Microbiology and Immunology , Virginia Commonwealth University , Richmond , VA , USA .; i Department of Biochemistry and Molecular Biology , Virginia Commonwealth University , Richmond , VA , USA .; j The Institute for Molecular Medicine , Virginia Commonwealth University , Richmond , VA , USA , and. Friedberg JW; d James P. Wilmot Cancer Center, University of Rochester , Rochester , NY , USA .; k Department of Medicine , University of Rochester , Rochester, NY , USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2016; Vol. 57 (3), pp. 635-43. Date of Electronic Publication: 2015 Oct 12.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
